# Es Follow Transgender Male Monitoring

> Provides monitoring schedule for transgender males on testosterone therapy, detailing timing of clinical visits, laboratory tests, and assessment for virilization and adverse reactions. It is triggered when a clinician manages a transgender male patient on gender‑affirming hormone therapy and needs to schedule appropriate follow‑up.

- Skill: `dromlakhani/es-follow-transgender-male-monitoring` (Agent Skill)
- Install (CLI): `npx skillmds@latest add dromlakhani/es-follow-transgender-male-monitoring`
- Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/es-follow-transgender-male-monitoring/raw
- Safety review: pending (external: skill-scanner PASS, skillspector PASS)
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: Coding & Dev Tools
- Author: dromlakhani (https://skillmd.com/u/dromlakhani)
- Updated: 2026-09-08
- Page: https://skillmd.com/skills/dromlakhani/es-follow-transgender-male-monitoring

---


# Follow monitoring protocol for transgender males on hormone therapy

## STEP 1 — Gather Information
Collect baseline demographics, medical history, current testosterone formulation and dose, physical exam (Tanner stage, signs of virilization, acne, blood pressure), and baseline labs (total testosterone, hematocrit/hemoglobin, fasting lipid panel, liver enzymes, vitamin D).  
**Action:** Schedule the first follow‑up visit in 3 months.

## STEP 2 — Rule In / Rule Out
Measure hematocrit at baseline and every 3 months during the first year, then 1‑2 times per year thereafter.  
**Decision:** If hematocrit ≥ 50% (or hemoglobin > 18 g/dL), rule in erythrocytosis; otherwise rule out.  
**Action:** If hematocrit ≥ 50%, proceed to dose reduction or therapeutic phlebotomy; otherwise continue routine monitoring.

## STEP 3 — Classify or Stratify
Assess serum testosterone level according to administration route: for enanthate/cypionate injections measure midway between injections; for gels measure ≥24 h after daily application; for undecanoate measure just before the next injection.  
**Classification:** Sub‑therapeutic (<400 ng/dL), therapeutic (400‑700 ng/dL), supratherapeutic (>700 ng/dL).  
**Action:** Adjust testosterone dose to maintain levels within the therapeutic range (400‑700 ng/dL).

## STEP 4 — Decide
Based on testosterone classification and hematocrit result, decide on next steps: maintain current dose if therapeutic and hematocrit <50%; reduce dose if supratherapeutic or hematocrit ≥50%; hold therapy and evaluate for other causes if hematocrit >54%; consider phlebotomy if symptomatic erythrocytosis persists.  
**Action:** Implement the decided dose adjustment and schedule the next laboratory check in 3 months if stable, or sooner if the dose was changed.

## Clinical Guardrails / Mimics / Pitfalls
- Avoid supraphysiologic testosterone (>1000 ng/dL) to limit erythrocytosis, cardiovascular risk, and sleep apnea.  
- Monitor fasting lipids and blood pressure every 3‑6 months; treat hypertension or dyslipidemia per standard guidelines.  
- Assess for signs of sleep apnea (snoring, daytime somnolence) at each visit.  
- Do not initiate testosterone in patients with uncontrolled hematocrit >54% without evaluation.  
- If testosterone is stopped, obtain bone mineral density measurement when osteoporosis risk factors exist.  
- Exclude pregnancy before starting therapy; note that transdermal testosterone requires application‑site rotation and level measurement no sooner than 1 week after daily application.  
- Do not rely solely on symptoms; laboratory confirmation of testosterone and hematocrit is required for dose decisions.

## Concrete Clinical Example
A 22‑year‑old transgender male begins testosterone enanthate 100 mg IM weekly. Baseline: testosterone 200 ng/dL, hematocrit 38%. At 3‑month visit, testosterone measured midway between injections is 620 ng/dL, hematocrit 44%, lipids unchanged. Classification: therapeutic; hematocrit <50%. Decision: maintain current dose. Next labs scheduled in 3 months.

**Source:** Endocrine Society Clinical Practice Guideline, “Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons,” Wylie C. Hembree et al., 2017, DOI: 10.1210/jc.2017-01658